The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was ...

TUESDAY, Dec. 17, 2024 (HealthDay News) -- Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with initiation of a dipeptidyl peptidase ...

Diabetic retinopathy (DR) remains the leading cause of vision loss and blindness in people of working age, in spite of the fact that current treatments are effective. Vision loss occurs in DR due ...

The risk for nonproliferative diabetic retinopathy progression was similar for empagliflozin vs DPP4i therapy. (HealthDay News) — Empagliflozin initiation is not associated with incident ...

Geriatrics and Aging. 2008;11(6):333-341. Proliferative diabetic retinopathy is clinically characterized by the growth of new blood vessels that arise from the optic disc and/or retina and ...

Treating diabetic retinopathy (DR) is still a significant challenge for clinicians and remains a leading cause of blindness worldwide. NovaGo Therapeutics is developing a human antibody therapy ...

Use of empagliflozin (Jardiance) was not linked to a lower risk of incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...

Diabetic retinopathy involves the changes for the blood vessels in your eye due to the high sugars that are in your body from diabetes, if you're a diabetic and you notice changes to your vision ...